These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pipeline and key clinical candidates for these companies:
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG’s cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 400 patients with Non-Muscle Invasive Bladder Cancer.
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
Recent news on these stocks:
September 17
Morgan Stanley raised the firm’s price target on CG Oncology to $79 from $56 and keeps an Overweight rating on the shares. The approval of Inlexzo and higher-than-expected price bolsters Morgan Stanley’s confidence in creto’s regulatory pathway ahead as well as peak sales potential, the analyst tells investors in a research note.
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Biotech Alert: Searches spiking for these stocks today
- CG Oncology price target raised to $79 from $56 at Morgan Stanley
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Buy Rating for CG Oncology: Creto’s Market Potential and Strategic Pricing Flexibility
- CG Oncology Highlights Drug Potential at Healthcare Conference